Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by Werba Rubin Papier Wealth Management

Werba Rubin Papier Wealth Management grew its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.7% in the third quarter, Holdings Channel.com reports. The institutional investor owned 14,095 shares of the biopharmaceutical company’s stock after buying an additional 367 shares during the quarter. Werba Rubin Papier Wealth Management’s holdings in Gilead Sciences were worth $1,182,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. DMC Group LLC raised its holdings in Gilead Sciences by 6.0% in the 3rd quarter. DMC Group LLC now owns 14,155 shares of the biopharmaceutical company’s stock valued at $1,187,000 after acquiring an additional 807 shares during the last quarter. Resonant Capital Advisors LLC acquired a new stake in shares of Gilead Sciences in the third quarter valued at approximately $1,261,000. Veracity Capital LLC purchased a new position in Gilead Sciences during the third quarter worth approximately $463,000. AA Financial Advisors LLC acquired a new position in Gilead Sciences during the third quarter worth $214,000. Finally, Mitsubishi UFJ Asset Management UK Ltd. grew its holdings in Gilead Sciences by 750.0% in the 3rd quarter. Mitsubishi UFJ Asset Management UK Ltd. now owns 17,000 shares of the biopharmaceutical company’s stock valued at $1,425,000 after buying an additional 15,000 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

GILD has been the topic of several analyst reports. Cantor Fitzgerald reiterated a “neutral” rating and set a $70.00 price target on shares of Gilead Sciences in a report on Monday, September 16th. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a research note on Thursday, August 15th. BMO Capital Markets increased their price target on shares of Gilead Sciences from $85.00 to $94.00 and gave the company an “outperform” rating in a research note on Thursday. Truist Financial lifted their price target on shares of Gilead Sciences from $82.00 to $83.00 and gave the company a “hold” rating in a research report on Thursday, August 15th. Finally, Evercore ISI upgraded Gilead Sciences to a “strong-buy” rating in a report on Friday, August 9th. Ten research analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $86.37.

Insiders Place Their Bets

In other news, insider Johanna Mercier sold 29,357 shares of the business’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the completion of the transaction, the insider now directly owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total value of $167,660.00. Following the sale, the insider now directly owns 100,189 shares in the company, valued at $8,398,843.87. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Johanna Mercier sold 29,357 shares of the company’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $83.78, for a total value of $2,459,529.46. Following the transaction, the insider now directly owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 36,847 shares of company stock worth $3,033,340 in the last quarter. 0.16% of the stock is owned by company insiders.

Gilead Sciences Trading Down 0.7 %

NASDAQ GILD opened at $86.72 on Friday. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.95 and a current ratio of 1.14. The firm has a market cap of $108.04 billion, a price-to-earnings ratio of 240.89, a PEG ratio of 2.98 and a beta of 0.18. The firm has a 50 day simple moving average of $81.06 and a 200-day simple moving average of $72.81. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $87.86.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating the consensus estimate of $1.61 by $0.40. The company had revenue of $6.95 billion during the quarter, compared to analysts’ expectations of $6.64 billion. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. Equities research analysts anticipate that Gilead Sciences, Inc. will post 3.78 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, September 27th. Investors of record on Friday, September 13th were paid a dividend of $0.77 per share. The ex-dividend date of this dividend was Friday, September 13th. This represents a $3.08 annualized dividend and a yield of 3.55%. Gilead Sciences’s payout ratio is 855.56%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.